Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
ID: 356719Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Oct 15, 2024, 12:00 AM UTC
  4. 4
    Due Mar 19, 2025, 12:00 AM UTC
Description

The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting R01 Clinical Trials. This initiative seeks to develop and evaluate innovative care models that effectively integrate services for HIV/AIDS, substance use disorders (SUD), and optional hepatitis, with the goal of enhancing healthcare delivery and improving health outcomes for affected individuals. The program aligns with the "Ending the HIV Epidemic: A Plan for America" initiative and emphasizes the importance of coordinated care in settings such as Federally Qualified Health Centers. Eligible applicants include various institutions and organizations, with an expected award budget of up to $2 million for fiscal year 2026 and a project duration of up to five years. Interested parties can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by March 19, 2025.

Point(s) of Contact
Files
Title
Posted
Oct 17, 2024, 10:15 AM UTC
The Department of Health and Human Services, through the National Institutes of Health, announces a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services." The program, specifically aimed at R01 Clinical Trials, intends to develop and evaluate enhanced care models that integrate services for HIV/AIDS, hepatitis (optional), and substance use disorders (SUD). The goal is to improve healthcare delivery and health outcomes for individuals at risk or affected by these co-occurring health challenges. Eligible applicants include higher education institutions, nonprofits, and government entities, among others. The expected award budget is up to $2 million for FY26, and the project period can last up to five years. Applications must deeply consider the integration of services and submit well-justified plans that address both HIV/AIDS and SUD outcomes, highlighting scalability and sustainability of models tested. Research proposals should focus on innovations that improve coordinated care in settings including Federally Qualified Health Centers and other community organizations. The RFA aligns with the "Ending the HIV Epidemic: A Plan for America" initiative, which aims to diagnose, treat, prevent, and respond to HIV trend dynamics. All applications will be rigorously evaluated based on scientific merit and feasibility to ensure impactful contributions to public health challenges.
Similar Opportunities
Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
HIV Prevention and Alcohol (R01 Clinical Trials Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at expanding HIV prevention strategies among populations affected by alcohol use. This initiative encourages research projects that explore the relationship between alcohol consumption and HIV risk behaviors, focusing on areas such as Pre-exposure Prophylaxis (PrEP) utilization, Treatment as Prevention (TasP), and the integration of preventive intervention strategies. The program is particularly significant for addressing health disparities among high-risk groups, including men who have sex with men (MSM) and women with high-risk partners. The NIH anticipates funding between $2 million for 2 to 4 awards, with a project period of up to five years. Interested applicants can submit their proposals through the NIH ASSIST system or Grants.gov, and should direct inquiries to grantsinfo@nih.gov. The application deadline is May 7, 2026.
HIV Prevention and Alcohol (R01 Clinical Trials Optional)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at enhancing the HIV/AIDS prevention toolkit for populations impacted by alcohol use. This initiative seeks to integrate effective prevention and treatment interventions while developing and testing new strategies to address the behavioral and biological risks associated with HIV acquisition, particularly among high-risk groups such as men who have sex with men and transgender individuals. The anticipated funding for fiscal year 2025 is $2 million, with 2-4 awards expected, and applications must be submitted through Grants.gov by May 7, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAS-25-208.html.
Ex Vivo Models for Studies at the Intersection of HIV and Addictive Substance Use (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for research focused on the neuroimmune mechanisms linking HIV and addictive substance use, specifically targeting HIV-associated neurological disorders (HAND). This grant aims to support innovative projects utilizing advanced ex vivo models derived from human induced pluripotent stem cells (hiPSC) to investigate how addictive substances influence HAND and HIV pathology, with an emphasis on cellular interactions, neurodegeneration, and inflammatory responses in the brain. The total funding available for this initiative is $2 million, and eligible applicants include educational institutions, nonprofits, government agencies, and foreign organizations. Applications are due by July 13, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-074.html.
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.